NCT03666559 2024-02-29
AGIR
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
Clinical Trials
13 trialsNCT06105658 2023-10-30
Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With AML
Anhui Provincial Hospital
Phase 2 Unknown
NCT04248595 2022-09-08
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML
Zhongda Hospital
Phase 2 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05008666 2021-08-17
Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH
Sun Yat-sen University
Phase 2 Unknown
NCT04899414 2021-05-24
Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma
Peking University
Phase 2 Unknown
NCT02124174 2021-04-26
Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS
Loyola University
Phase 2 Unknown
NCT04052659 2021-03-09
Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL
Peking University
Phase 2 Unknown
NCT04541277 2020-09-09
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
Phase 2 Unknown
NCT03719989 2018-10-25
EPIC
Seoul National University Hospital
Phase 2 Unknown
NCT02275663 2015-01-06
Azacytidine Plus FLAG for Relapsed or Refractory AML
King Fahad Medical City
Phase 2 Unknown
NCT01556477 2012-03-16
The Efficacy of Azacitidine +/- Lenalidomide in High-risk Myelodysplastic Syndrome (MDS)and Acute Myeloid Leukemia (AML) With Del(5q).
Nordic MDS Group
Phase 2 Unknown
NCT00728520 2008-08-06
Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy
Kansas City Veteran Affairs Medical Center
Phase 2 Unknown